Barriers to Levodopa Use in Parkinson Disease

Video content above is prompted by the following:

Advancements in Levodopa-Based Continuous Subcutaneous Infusion Therapy: Executive Summary for Physicians

Pharmacokinetic Challenges With Oral Levodopa

Oral levodopa formulations face several pharmacokinetic limitations that have necessitated the development of subcutaneous delivery options:

• Short half-life: Levodopa’s 1- to 2-hour plasma half-life necessitates frequent dosing
• Erratic gastric emptying: Variable absorption due to unpredictable gastric transit
• Competition with dietary amino acids for intestinal and blood-brain barrier transport
• Narrow therapeutic window: Small range between efficacy and adverse effects
• OFF periods: Declining plasma levels between doses lead to symptom reemergence
• Pulsatile stimulation: Nonphysiological dopamine receptor stimulation contributes to motor complications
• Advanced disease complications: Gastric dysmotility increases as disease progresses

Benefits of Continuous Subcutaneous Infusion

The subcutaneous route addresses these challenges by:

• Providing stable plasma levodopa concentrations
• Bypassing gastrointestinal absorption issues
• Reducing motor fluctuations and OFF periods
• Enabling more precise, individualized dosing
• Offering a less invasive alternative to surgical interventions

These advancements allow for more personalized treatment approaches that can significantly improve quality of life for patients experiencing motor symptoms.